QIAGEN Launches QuantiFERON-EBV RUO Test to Advance Research on Cell-Mediated Immune Responses to Epstein-Barr Virus

QuantiFERON-EBV RUO helps researchers understand Epstein-Barr virus (EBV) infection and related malignancies, providing a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases by measuring T cell responses to EBV, providing Valuable information provides insight into the role of viruses in these conditions // Further expanding QuantiFERON’s cell-mediated immune response testing portfolio beyond TB

VENLO, the Netherlands, Oct. 4, 2023 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QuantiFERON-EBV RUO (Research Use Only) assay. Various epidemiological studies estimate that Epstein-Barr virus (EBV), or human herpesvirus type 4, is positive in more than 90% of the global population and is an important pathogen in organ transplant recipients.

This new addition to the QuantiFERON assay portfolio is designed to support the study of EBV infection and EBV-associated malignancies by utilizing highly specific EBV antigens to stimulate cell-mediated immune responses, thereby providing a dynamic view of host-virus active immune interactions. .

EBV is implicated in diseases ranging from infectious mononucleosis to EBV-associated tumors and tumor-like lesions. In organ transplant recipients, EBV is associated with posttransplant lymphoproliferative disease (PTLD), a potentially fatal complication after solid organ transplantation. It is estimated that more than 80% of PTLD cases in Europe and the United States are related to EBV. (1)

Additionally, there is growing evidence of a potential link between EBV and multiple sclerosis (MS), a chronic disease of the central nervous system estimated to affect more than 2.8 million people worldwide. EBV T cell measurements in MS may have a potential role in understanding disease progression, treatment monitoring, and developing customized treatments. (2)

“The QuantiFERON-EBV RUO test represents a major advance in our understanding of the complex relationship between EBV and the immune system,” said Jean-Pascal Viola, senior vice president and head of the Molecular Diagnostics business area at QIAGEN. “This test opens the door to innovative research. opens the door to delivering insights that can revolutionize patient care by guiding customized treatments across various areas of medicine, including oncology and autoimmune diseases.”

T cells play a crucial role in controlling and eliminating the virus, and an effective T cell response helps determine the course and severity of EBV infection. Measuring T cell responses to EBV can help researchers better understand the immune response to the virus. Specifically, in transplant patients, it has the potential to personalize immunosuppressive therapy, stratify the risk of EBV-induced disease, assist clinicians in tailoring the timing of testing and monitoring, and assess the efficiency and durability of future EBV vaccines.

QuantiFERON-EBV RUO uses a combination of CD4+ and CD8+ antigens specific for the EBV nuclear antigen protein to stimulate lymphocytes in heparinized whole blood. This approach is different but complementary to traditional testing, which focuses on detecting viral DNA or antibodies produced in response to the virus.

Growing Portfolio of QuantiFERON Cell-Mediated Immune Response Tests

The new assay adds to QuantiFERON’s growing portfolio of cell-mediated immune response tests. QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, performing millions of TB tests every year. QuantiFERON SARS-CoV-2 identifies immune responses to COVID-19, and QuantiFERON-CMV is an indirect test for cytomegalovirus infection in transplant patients. The QuantiFERON monitor assesses non-pathogen-specific cell-mediated immune responses in transplant patients. In addition, QIAGEN and DiaSorin collaborated to develop the LIAISON LymeDetect test, which uses QuantiFERON technology to detect early-stage Lyme Borrelia infection. (3)

QIAGEN’s QuantiFERON technology is a unique method for detecting cell-mediated immune responses from whole blood samples. It works by identifying specific T cells in individuals who have been exposed to infectious pathogens. When infection-specific antigens bind to the blood, antigen-specific T cells are rapidly re-stimulated, resulting in the secretion of interferon-gamma (IFN-γ), which can be measured as a marker of immune response. Testing includes QuantiFERON blood collection tubes using its proprietary stimulation principle and the QuantiFERON ELISA detection system to measure interferon-gamma production.

For more information about QIAGEN QuantiFERON-EBV RUO products, please visit https://www.qiagen.com/us/products/diagnostics-and-clinical-research/transplant/quantiferon-transplant/quantiferon-ebv-bct-spp- Ruo.


QIAGEN NV, a holding company headquartered in the Netherlands, is the world’s leading provider of Sample to Insight solutions, helping customers gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Detection technologies make these biomolecules visible and available for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions bring these together into a seamless and cost-effective workflow. QIAGEN provides solutions in the fields of molecular diagnostics (human healthcare) and life sciences (academia, pharmaceutical R&D and industrial applications, primarily forensics) to more than 500,000 customers worldwide. As of June 30, 2023, QIAGEN had more than 6,100 employees in more than 35 locations around the world.For more information see http://www.qiagen.com.

forward-looking statements

Certain statements contained in this press release may be deemed to be forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Any statements contained herein regarding QIAGEN’s products (including products to address the COVID-19 pandemic), timing of launch and development, marketing and/or regulatory approvals, financial and operating prospects, growth and expansion, collaborations, markets, Strategies or operating results, including without limitation expected adjusted net sales and adjusted diluted earnings results, are forward-looking statements, and such statements are based on current expectations and assumptions and involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks related to growth management and international operations (including the impact of currency fluctuations, regulatory processes and reliance on logistics), variability in operating results and allocation among customer categories, commercial Developing markets for our products for customers in academia, pharmaceuticals, applied testing and molecular diagnostics; Changing relationships with customers, suppliers and strategic partners; Competition; Rapid or unexpected changes in technology; Fluctuations in demand for QIAGEN’s products, including fluctuations due to general economic conditions, customer funding levels and timing, budgets and other factors); the ability of our products to obtain regulatory approval; the difficulty of successfully applying QIAGEN’s products into integrated solutions and producing such products; QIAGEN the ability to identify and develop new products and to differentiate and protect our products from those of our competitors; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; government actions, global or regional economic developments, weather or traffic delays, natural Disasters, political or public health crises, including the extent and duration of the COVID-19 pandemic and its impact on demand for our products and other aspects of our business, or other force majeure events; and anticipated benefits related to recent or upcoming acquisitions the possibility that we may not materialize as anticipated; and the other factors discussed under the heading “Risk Factors” in Item 3 of our most recent Annual Report on Form 20-F. For further information, please see the discussions in reports QIAGEN has filed with or furnished to the U.S. Securities and Exchange Commission.

Category: Enterprise

(1) Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorders in solid organ transplant recipients – BCSH and BTS guidelines. Br J Haematol. 2010;149:675–692. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08161.x
(2) Bar-Or, Amit et al., “Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies,” Trends in Molecular Medicine, March 2020, published December 2019; https://doi .org/10.1016/j.molmed.2019.11.003
(3) Product availability may vary by country based on regulations and approvals.

Source link

Leave a Comment